International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

TitleInternational harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Publication TypeJournal Article
Year of Publication2021
AuthorsCosta, LJ, Derman, BA, Bal, S, Sidana, S, Chhabra, S, Silbermann, R, Ye, JC, Cook, G, Cornell, RF, Holstein, SA, Shi, Q, Omel, J, Callander, NS, Chng, WJoo, Hungria, V, Maiolino, A, Stadtmauer, E, Giralt, S, Pasquini, M, Jakubowiak, AJ, Morgan, GJ, Krishnan, A, Jackson, GH, Mohty, M, Mateos, MVictoria, Dimopoulos, MA, Facon, T, Spencer, A, San Miguel, J, Hari, P, Usmani, SZ, Manier, S, McCarthy, P, Kumar, S, Gay, F, Paiva, B
JournalLeukemia
Volume35
Issue1
Pagination18-30
Date Published2021 01
ISSN1476-5551
KeywordsClinical Trials as Topic, Diagnostic Imaging, Disease Management, Drug Collateral Sensitivity, Global Health, Humans, Molecular Diagnostic Techniques, Multiple Myeloma, Neoplasm, Residual, Neoplastic Cells, Circulating, Outcome Assessment, Health Care, Population Surveillance, Reproducibility of Results, Smoldering Multiple Myeloma, Time Factors
Abstract

Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity across clinical trials in how MRD is assessed and reported, creating challenges for data interpretation and for the design of subsequent studies. We convened an international panel of MM investigators to harmonize how MRD should be assessed and reported in MM clinical trials. The panel provides consensus on which MM trials should include MRD, the recommended time points for MRD assessment, and expected analytical validation for MRD assays. We subsequently outlined parameters for reporting MRD results implementing the intention-to-treat principle. The panel provides guidance regarding the incorporation of newer peripheral blood-based and imaging-based approaches to detection of residual disease. Recommendations are summarized in 13 consensus statements that should be followed by sponsors, investigators, editors, and reviewers engaged in designing, performing, and interpreting MM trials.

DOI10.1038/s41375-020-01012-4
Alternate JournalLeukemia
PubMed ID32778736
Grant ListKL2 TR003143 / TR / NCATS NIH HHS / United States